Seeking Alpha

Wedbush initiates coverage on NPS Pharmaceuticals (NPSP) at Outperform with a lofty $14 price...

Wedbush initiates coverage on NPS Pharmaceuticals (NPSP) at Outperform with a lofty $14 price target. Analysts with the firm expect that not only will Gattex win FDA approval, but that the cancer drug will also deliver $252M in global revenue in 2015.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs